Albiglutide belongs to the same class of injectable
GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon,
from Bristol-Myers Squibb and AstraZeneca.
A positive recommendation for a drug by the European Medicines
Agency is generally followed by a marketing authorization by the
European Commission. GSK said a final decision was anticipated later
Last year regulators in the United States pushed back an approval
decision on the drug until April 15.
(Reporting by Paul Sandle; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.